LEADER 02764nam 2200577 450 001 9910779616103321 005 20230626010300.0 010 $a84-9029-969-2 035 $a(CKB)2550000001046518 035 $a(OCoLC)847621019 035 $a(CaPaEBR)ebrary10679795 035 $a(MiAaPQ)EBC3210201 035 $a(FINmELB)ELB56232 035 $aEBL7016014 035 $a(AU-PeEL)EBL7016014 035 $a(MiAaPQ)EBC7016014 035 $a(EXLCZ)992550000001046518 100 $a20230626d2013 uy 0 101 0 $aspa 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAprendizaje Social y Personalizado $eConectarse para Aprender /$fJordi Jubany i Vila ; pro?logos de Pere Darder y Nu?ria Vila? 205 $aFirst edition. 210 1$aBarcelona, Spain :$cEditorial UOC,$d[2013] 210 4$d©2013 215 $a1 online resource (143 p.) 225 1 $aColeccio?n Educacio?n y sociedad red 300 $aDescription based upon print version of record. 311 $a84-9029-025-3 330 8 $a¿Redactas normalmente cartas o envías correos electrónicos? ¿Vas a revelar las fotografías o utilizas la cámara del móvil? ¿Consultas a menudo los volúmenes de la enciclopedia o buscas tus dudas por Internet? ¿Lees en pantallas? ¿Formas parte de alguna red social? La digitalización y el hecho de estar conectados a otras personas nos pueden ayudar a aprender lo que necesitamos, lo que nos interesa, y a desarrollar las competencias personales, comunicativas y metodológicas. En el presente libro se exponen los marcos de referencia que sirven para desarrollar actividades interesantes e innovadoras con la ayuda de las TIC (Tecnologías de la Información y de la Comunicación). Se facilitan recursos, experiencias y propuestas para aprovechar todo este potencial al ritmo de cada uno. Las TIC permiten personalizar los aprendizajes y, al mismo tiempo, aprender socialmente. La obra se dirige a los docentes y a toda persona interesada en el aprendizaje, el conocimiento, la identidad, la colaboración y las nuevas tecnologías. 410 0$aColeccio?n Educacio?n y sociedad red. 606 $aEducational technology 606 $aInternet in education 606 $aWeb 2.0 615 0$aEducational technology. 615 0$aInternet in education. 615 0$aWeb 2.0. 676 $a371.33 700 $aJubany$b Jordi$01503174 702 $aDarder$b Pere 702 $aVila?$b Nu?ria 712 02$ae-libro, Corp. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910779616103321 996 $aAprendizaje Social y Personalizado$93731398 997 $aUNINA LEADER 04854nam 22006975 450 001 9910254282103321 005 20200704021517.0 010 $a3-319-46076-5 024 7 $a10.1007/978-3-319-46076-5 035 $a(CKB)3710000001388712 035 $a(DE-He213)978-3-319-46076-5 035 $a(MiAaPQ)EBC4865992 035 $a(PPN)201473569 035 $a(EXLCZ)993710000001388712 100 $a20170525d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aQuantitative Decisions in Drug Development /$fby Christy Chuang-Stein, Simon Kirby 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (XV, 248 p. 27 illus., 11 illus. in color.) 225 1 $aSpringer Series in Pharmaceutical Statistics,$x2366-8695 311 $a3-319-46075-7 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aClinical Testing of a New Drug -- A Frequentist Decision-making Framework -- Characteristics of a Diagnostic Test -- The Parallel Between Clinical Trials and Diagnostic Tests -- Incorporating Information from Completed Trials in Future Trial Planning -- Choosing Metrics Appropriate for Different Stages of Drug Development -- Designing Proof-of-Concept Trials with Desired Characteristics -- Designing Dose-response Studies with Desired Characteristics -- Designing Confirmatory Trials with Desired Characteristics -- Designing Phase 4 Trials -- Other Metrics That Have Been Proposed to Optimize Drug Development Decisions -- Discounting Prior Results to Account for Selection Bias -- Index -- Appendix. 330 $aThis book offers a high-level treatise of evidence-based decisions in drug development. Because of the inseparable relationship between designs and decisions, a good portion of this book is devoted to the design of clinical trials. The book begins with an overview of product development and regulatory approval pathways. It then discusses how to incorporate prior knowledge into study design and decision making at different stages of drug development. The latter include selecting appropriate metrics to formulate decisions criteria, determining go/no-go decisions for progressing a drug candidate to the next stage and predicting the effectiveness of a product. Lastly, it points out common mistakes made by drug developers under the current drug-development paradigm. The book offers useful insights to statisticians, clinicians, regulatory affairs managers and decision-makers in the pharmaceutical industry who have a basic understanding of the drug-development process and the clinical trials conducted to support drug-marketing authorization. The authors provide software codes for select analytical approaches discussed in the book. The book includes enough technical details to allow statisticians to replicate the quantitative illustrations so that they can generate information to facilitate decision-making themselves. 410 0$aSpringer Series in Pharmaceutical Statistics,$x2366-8695 606 $aStatistics 606 $aBiometry 606 $aPharmacy 606 $aPharmaceutical technology 606 $aQuality control 606 $aReliability 606 $aIndustrial safety 606 $aStatistics for Life Sciences, Medicine, Health Sciences$3https://scigraph.springernature.com/ontologies/product-market-codes/S17030 606 $aBiostatistics$3https://scigraph.springernature.com/ontologies/product-market-codes/L15020 606 $aDrug Safety and Pharmacovigilance$3https://scigraph.springernature.com/ontologies/product-market-codes/H69010 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aQuality Control, Reliability, Safety and Risk$3https://scigraph.springernature.com/ontologies/product-market-codes/T22032 615 0$aStatistics. 615 0$aBiometry. 615 0$aPharmacy. 615 0$aPharmaceutical technology. 615 0$aQuality control. 615 0$aReliability. 615 0$aIndustrial safety. 615 14$aStatistics for Life Sciences, Medicine, Health Sciences. 615 24$aBiostatistics. 615 24$aDrug Safety and Pharmacovigilance. 615 24$aPharmaceutical Sciences/Technology. 615 24$aQuality Control, Reliability, Safety and Risk. 676 $a519.5 700 $aChuang-Stein$b Christy$4aut$4http://id.loc.gov/vocabulary/relators/aut$0766774 702 $aKirby$b Simon$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910254282103321 996 $aQuantitative Decisions in Drug Development$92283937 997 $aUNINA